What is Micrima?
Founded in 2006, Micrima operates at the intersection of advanced physics and oncology. The company specializes in the development of non-ionizing radio-wave imaging systems designed to provide a safer, more comfortable alternative to traditional mammography. By leveraging high-frequency radio waves, Micrima's technology aims to improve the sensitivity and specificity of breast cancer screening, particularly in dense breast tissue where conventional methods often face limitations. As a key player in the UK healthtech ecosystem, the company maintains a strong focus on clinical validation and regulatory milestones, positioning itself as a disruptive force in the global medical diagnostics market.
How much funding has Micrima raised?
Micrima has raised a total of $14.2M across 3 funding rounds:
Unspecified
$3.4M
Private Equity
$5.6M
Unspecified
$5.2M
Unspecified (2016): $3.4M with participation from Angel CoFund, Technology Venture Partners, University of Bristol Enterprise Fund, and Swarraton Partners
Private Equity (2018): $5.6M led by Angel CoFund, Venture Founders, and Technology Venture Partners
Unspecified (2021): $5.2M supported by Technology Venture Partners LLC
Key Investors in Micrima
Angel CoFund
A £100M investment vehicle that partners with sector-focused angel investors to provide capital to high-growth UK businesses.
Technology Venture Partners
A venture capital and private equity firm focused on identifying and scaling innovative technology-driven enterprises.
University of Bristol Enterprise Fund
An institutional investment arm associated with a leading research university, supporting the commercialization of academic breakthroughs.
What's next for Micrima?
The infusion of capital from the latest financing round is expected to accelerate Micrima's operational roadmap, specifically targeting the expansion of its clinical trial footprint and the refinement of its diagnostic algorithms. As the company transitions from a research-heavy development phase to a commercialization-ready enterprise, management will likely prioritize regulatory approvals in key international markets. The strategic focus remains on integrating its radio-wave technology into standard clinical workflows, thereby addressing the critical need for more accessible and accurate breast cancer screening solutions. Continued support from its established investor base provides the necessary runway to scale manufacturing and build the infrastructure required for a global market entry.
See full Micrima company page
